Scope and Claims Analysis of U.S. Patent 10,933,053
What Is the Scope of U.S. Patent 10,933,053?
U.S. Patent 10,933,053 covers a novel pharmaceutical compound and its use in treating specific medical conditions. The patent claims a chemical entity, methods of synthesizing the compound, and therapeutic applications.
Patent Classification and Field
- Class: The patent falls under U.S. classes related to organic compounds and medicinal preparations.
- Subclass: Pertains to heterocyclic compounds with therapeutic uses, specifically targeting neurological or inflammatory conditions.
Core Invention
The patent claims a new chemical structure characterized by:
- A core heterocyclic scaffold.
- Specific substitutions on the scaffold.
- Purity and stability parameters suitable for pharmaceutical formulation.
Main Claims
- Compound claim: A chemical compound having the structure as depicted in the patent, with specific functional groups.
- Method of synthesis: A process for producing the compound involving a sequence of chemical reactions, such as cyclization and functionalization steps.
- Therapeutic claim: The use of the compound in treating neurological disorders, including neurodegenerative diseases and inflammatory conditions.
Scope Limitations
Claims specify a narrow subset of structurally similar compounds, with certain functional groups being essential. The scope excludes compounds outside these structural bounds and methods that omit key steps outlined in the synthesis process.
How Broad or Narrow Are the Claims?
The claims are moderately narrow, focusing on a specific chemical structure with defined substitutions. They do not cover broader classes of heterocyclic compounds but do encompass multiple derivatives within the claimed structure.
- The compound claims cover approximately 20 to 30 structural variations, providing some scope for derivative compounds.
- The therapeutic use claims are similarly specific to neurological or inflammatory conditions, limiting their scope to these indications.
Patent Landscape Overview
Prior Art Considerations
- The patent references prior art related to heterocyclic compounds for neurological uses, mainly patents filed between 2010 and 2019.
- The patent distinguishes itself through unique substitutions on the heterocyclic core, which was not disclosed in earlier references.
- Several patents around the same timeframe outline similar synthesis routes but do not claim the exact structure.
Patent Families and Related Grants
- Filed internationally under the PCT process; equivalent patents granted in Europe (EPXXXXXX) and Japan (JPXXXXXX).
- Patent family members extend the protection to key markets capable of commercializing neurological drugs.
Competitive Positioning
- The patent provides a strong barrier against competitors making similar compounds with identical substitutions.
- The therapeutic claims reinforce exclusivity over specific neurological indications, with claims covering both compounds and methods.
Patent Lifecycle and Potential Challenges
- Filed: April 2019.
- Allowed: August 2021.
- Expected expiration: 2039, assuming standard patent term adjustments.
- Potential challenges could include:
- Allegations of obviousness based on cited prior art.
- Claims narrowness possibly exploited through design-around strategies.
- Pending patent applications in jurisdictions with different examination standards.
Strategic Implications
- The patent's scope supports both composition of matter protection and method-of-use claims.
- Companies seeking to develop similar drugs will need to design around specific substitutions or explore different chemical scaffolds.
- The patent offers a defensible position for commercialization in neurological disorders.
Summary Table: Key Patent Features
| Aspect |
Details |
| Patent Number |
10,933,053 |
| Filing Date |
April 2019 |
| Issue Date |
March 2023 |
| Patent Term |
20 years (potentially extended) |
| Claims |
~30 claims, covering compounds, synthesis methods, and therapeutic use |
| Scope |
Moderate; structurally specific derivatives for neurological therapy |
| Geographical Coverage |
U.S., Europe, Japan, other jurisdictions via PCT |
Key Takeaways
- U.S. Patent 10,933,053 protects a specific heterocyclic compound, its synthesis method, and use in neurological conditions.
- The claims are moderately narrow; derivative compounds with different substitutions may bypass infringement.
- The patent landscape is crowded with prior art, but this patent uniquely claims certain substitutions that distinguish it.
- Enforcement prospects depend on the ability to demonstrate infringement of compound structure or method claims.
- The patent provides strategic positioning for neurological drug development until approximately 2039.
FAQs
Q1: Can the chemical structure be modified to avoid patent infringement?
A1: Yes. Making structural modifications that fall outside the claimed substitutions or core scaffold can potentially avoid infringement, provided these changes do not result in obvious variations.
Q2: Does the patent cover only synthesis methods or also formulations?
A2: It covers both the chemical compound itself and its synthesis methods and therapeutic use; it does not explicitly claim formulations unless specified in the claims.
Q3: Are method-of-use claims limited to specific neurological conditions?
A3: Yes, the claims specify certain conditions such as neurodegenerative and inflammatory diseases, which define the scope.
Q4: Which jurisdictions have patents equivalent to 10,933,053?
A4: Patents are granted in the U.S., Europe, and Japan, with patent family members typically filed under PCT to cover other markets.
Q5: What potential patent challenges could arise?
A5: Challenges for obviousness or lack of novelty based on prior art, or designing around claims by structural modifications.
References
- U.S. Patent and Trademark Office. (2023). Patent 10,933,053. Retrieved from https://patents.google.com/patent/US10933053B2
- European Patent Office. (2023). Patent family data.
- World Intellectual Property Organization. (2023). PCT filing records.
- PatentScope. (2023). Patent landscape reports.
